IP Library Granted Patent US 6,841,167
Granted Patent B1
US 6,841,167 · App. 10/031,531 · Granted Jan 11, 2005

β-carboline pharmaceutical compositions

Assignee: Lilly Icos LLC.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,841,167
App. No.
10/031,531
Granted
Jan 11, 2005
Kind
B1
Abstract

A soft capsule containing a solution or suspension of a PDE5 inhibitor, and use of the capsule in treating sexual dysfunction.

Claims (17)

1. A soft capsule comprising:

(a) a shell comprising gelatin, wherein said shell encapsulates

(b) a suspension pharmaceutical formulation comprising about 1% to about 45% by weight of solid particles of an active compound having a structural formula

and a pharmaceutically acceptable carrier comprising (i) a pharmaceutically acceptable solvent selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, a C 8 -C 10 monoglyceride, and mixtures thereof, and (ii) a suspending agent comprising a saturated polyglycolyzed glyceride.

2. The capsules of claim 1 wherein the active compound is present as a free drug.

3. The capsules of claim 1 wherein the pharmaceutically acceptable carrier further comprises a polyvinylpyrrolidone.

4. The capsules of claim 1 wherein the pharmaceutical formulation comprises about 2% to about 2.8% by weight of the active compound, about 3% to about 8% by weight propylene glycol, and about 90% to about 95% by weight polyethylene glycol 400.

5. The capsules of claim 1 wherein the solvent further comprises C 8 -C 10 monoglycerides.

6. The capsules of claim 1 wherein the pharmaceutically acceptable carrier further comprises a surfactant.

7. The capsules of claim 5 wherein the pharmaceutical formulation comprises about 3% to about 8% by weight of the active compound, about 5% to about 8% by weight propylene glycol, about 10% to about 60% by weight of C 8 -C 10 monoglycerides, and about 30% to about 75% by weight of a saturated polyglycolyzed glyceride.

8. The capsules of claim 1 wherein the active compound is present in an amount of about 1 to about 20 mg per capsule.

9. The capsules of claim 1 wherein the active compound is present in an amount of about 2 to about 20 mg per capsule.

10. The capsules of claim 1 wherein the active compound is present in an amount of about 5 to about 15 mg per capsule.

11. The capsules of claim 1 wherein the active compound is present in an amount of about 10 mg per capsule.

12. A method of treating sexual dysfunction in a patient in need thereof comprising administering to the patient a capsule of claim 1 .

13. The method of claim 12 wherein the sexual dysfunction is male erectile dysfunction.

14. The method of claim 12 wherein the sexual dysfunction is female arousal disorder.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2013
From: LILLY ICOS LLC
To: ICOS CORPORATION
Reel/Frame 031060/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2002
From: ANDERSON, NEIL R.; GULLAPALLI, RAMPURNA P.
To: LILLY ICOS LLC, A DELAWARE CORPORATION
Reel/Frame 012818/0640 →
Continuity (1)
Provisional Application 6014692400 · Aug 3, 1999